Modeling approach to investigate the effect of neonatal Fc receptor binding affinity and anti-therapeutic antibody on the pharmacokinetic of humanized monoclonal anti-tumor necrosis factor-α IgG antibody in cynomolgus monkey

European Journal of Pharmaceutical Sciences

Volumn 51, Issue 1, 2014, Pages 51-58

  Ng, Chee M ^a,b   Loyet, Kelly M ^c   Iyer, Suhasini ^c   Fielder, Paul J ^c   Deng, Rong ^c  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c GENENTECH INC   (United States)

Author keywords

Anti therapeutic antibody; FcRn Tumor necrosis factor alpha; IgG antibody; Immunogenicity; Pharmacokinetic and pharmacodynamic modeling; Therapeutic monoclonal

Indexed keywords

ADALIMUMAB; ANTIBODY; FC RECEPTOR; IMMUNOGLOBULIN G ANTIBODY; THERAPEUTIC ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; DRUG EXPOSURE; MACACA FASCICULARIS; MODEL; NONHUMAN; PARAMETERS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL;

ANTI-THERAPEUTIC ANTIBODY; FCRN; IMMUNOGENICITY; PHARMACOKINETIC AND PHARMACODYNAMIC MODELING; THERAPEUTIC MONOCLONAL IGG ANTIBODY; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALS; ANTIBODIES, MONOCLONAL; HISTOCOMPATIBILITY ANTIGENS CLASS I; MACACA FASCICULARIS; PROTEIN BINDING; RECEPTORS, FC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84884911158     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2013.08.033     Document Type: Article

References (43)

1. R.J. Bauer, and S. Guzy Monte Carlo Parametric Expectation Maximization (MC-PEM) method for analyzing population pharmacokinetic/pharmacodynamic (PK/PD) data D.Z. D'Argenio, Advanced Methods of Pharmacokinetic and Pharamcodynamic System Analysis 2004 Kluwer Academic Publishers Boston 135 163
2. S.L. Beal Ways to fit a PK model with some data below the quantification limit J. Pharmacokinet Pharmacodyn. 28 2001 481 504 (Pubitemid 33151426)
3. M. Bergstrand, and M.O. Karlsson Handling data below the limit of quantification in mixed effect models AAPS J. 11 2009 371 380
4. P.L. Bonate, C. Sung, K. Welch, and S. Richards Conditional modeling of antibody titers using a zero-inflated poisson random effects model: application to Fabrazyme J. Pharmacokinet Pharmacodyn. 36 2009 443 459
5. R. Braeckman Pharmacokinetics and pharmacodynamics of protein therapeutics R. Reid, Peptide and Protein Drug Analysis 2000 Marcel Dekker New York 633 669
6. F.W. Brambell, W.A. Hemmings, and I.G. Morris A theoretical model of gamma-globulin catabolism Nature 203 1964 1352 1354
7. W.P. Burmeister, A.H. Huber, and P.J. Bjorkman Crystal structure of the complex of rat neonatal Fc receptor with Fc Nature 372 1994 379 383 (Pubitemid 24363442)
8. W. Byon, C.V. Fletcher, and R.C. Brundage Impact of censoring data below an arbitrary quantification limit on structural model misspecification J. Pharmacokinet Pharmacodyn. 35 2008 101 116 (Pubitemid 351420764)
9. W.F. Dall'Acqua, R.M. Woods, E.S. Ward, S.R. Palaszynski, N.K. Patel, Y.A. Brewah, H. Wu, P.A. Kiener, and S. Langermann Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences J. Immunol. 169 2002 5171 5180 (Pubitemid 35217187)
10. W.F. Dall'Acqua, P.A. Kiener, and H. Wu Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn) J. Biol. Chem. 281 2006 23514 23524 (Pubitemid 44274126)
11. R. Deng, K.M. Loyet, S. Lien, S. Iyer, L.E. DeForge, F.P. Theil, H.B. Lowman, P.J. Fielder, and S. Prabhu Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{alpha} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys Drug Metab. Dispos.: Biol. Fate Chem. 38 2010 600 605
12. P.H. Ehrlich, Z.A. Moustafa, J.C. Justice, K.E. Harfeldt, R.L. Kelley, and L. Ostberg Characterization of human monoclonal antibodies directed against hepatitis B surface antigen Hum. Antibodies Hybridomas 3 1992 2 7
13. H. Frost Antibody-mediated side effects of recombinant proteins Toxicology 209 2005 155 160 (Pubitemid 40568643)
14. V. Ghetie, and E.S. Ward Multiple roles for the major histocompatibility complex class I-related receptor FcRn Annu. Rev. Immunol. 18 2000 739 766 (Pubitemid 30365396)
15. M.I. Gregersen, H. Sear, R.A. Rawson, S. Chien, and G.L. Saiger Cell volume, plasma volume, total blood volume and F cells factor in the rhesus monkey Am. J. Physiol. 196 1959 184 187
16. R.J. Hansen, and J.P. Balthasar Pharmacokinetic/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia J. Pharm. Sci. 92 2003 1206 1215 (Pubitemid 36676467)
17. P.R. Hinton, M.G. Johlfs, J.M. Xiong, K. Hanestad, K.C. Ong, C. Bullock, S. Keller, M.T. Tang, J.Y. Tso, M. Vasquez, and N. Tsurushita Engineered human IgG antibodies with longer serum half-lives in primates J. Biol. Chem. 279 2004 6213 6216 (Pubitemid 38248752)
18. P.R. Hinton, J.M. Xiong, M.G. Johlfs, M.T. Tang, S. Keller, and N. Tsurushita An engineered human IgG1 antibody with longer serum half-life J. Immunol. 176 2006 346 356 (Pubitemid 43023280)
19. R.P. Junghans, and C.L. Anderson The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor Proc. Natl. Acad. Sci. USA 93 1996 5512 5516
20. I.A. Khalil, K. Kogure, H. Akita, and H. Harashima Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery Pharmacol. Rev. 58 2006 32 45
21. L.A. Khawli, M.M. Mizokami, J. Sharifi, P. Hu, and A.L. Epstein Pharmacokinetic characteristics and biodistribution of radioiodinated chimeric TNT-1, -2, and -3 monoclonal antibodies after chemical modification with biotin Cancer Biother. Radiopharm. 17 2002 359 370
22. J.K. Kim, M. Firan, C.G. Radu, C.H. Kim, V. Ghetie, and E.S. Ward Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn Eur. J. Immunol. 29 1999 2819 2825 (Pubitemid 30099006)
23. T.T. Kuo, K. Baker, M. Yoshida, S.W. Qiao, V.G. Aveson, W.I. Lencer, and R.S. Blumberg Neonatal Fc receptor: from immunity to therapeutics J. Clin. Immunol. 30 2010 777 789
24. F. Labat-Moleur, A.M. Steffan, C. Brisson, H. Perron, O. Feugeas, P. Furstenberger, F. Oberling, E. Brambilla, and J.P. Behr An electron microscopy study into the mechanism of gene transfer with lipopolyamines Gene Ther. 3 1996 1010 1017 (Pubitemid 26397476)
25. H.J. Lee, and W.M. Pardridge Monoclonal antibody radiopharmaceuticals: cationization, pegylation, radiometal chelation, pharmacokinetics, and tumor imaging Bioconjug. Chem. 14 2003 546 553 (Pubitemid 36597364)
26. K.M. Loyet, R. Deng, W.C. Liang, Y. Wu, H.B. Lowman, and L.E. DeForge Technology comparisons for anti-therapeutic antibody and neutralizing antibody assays in the context of an anti-TNF pharmacokinetic study J. Immunol. Methods 345 2009 17 28
27. I. Nestorov Clinical pharmacokinetics of tumor necrosis factor antagonists J. Rheumatol. Suppl. 74 2005 13 18 (Pubitemid 40365775)
28. C.M. Ng, A. Joshi, R.L. Dedrick, M.R. Garovoy, and R.J. Bauer Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis Pharm. Res. 22 2005 1088 1100 (Pubitemid 41127066)
29. C.M. Ng, S. Bai, C.H. Takimoto, M.T. Tang, and A.W. Tolcher Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-alpha(5)beta (1) integrin monoclonal antibody (volociximab) in cancer patients Cancer Chemother. Pharmacol 2009
30. C.M. Ng, S. Bai, C.H. Takimoto, M.T. Tang, and A.W. Tolcher Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-alpha5beta1 integrin monoclonal antibody (volociximab) in cancer patients Cancer Chemother. Pharmacol. 65 2010 207 217
31. M.A. Palladino, F.R. Bahjat, E.A. Theodorakis, and L.L. Moldawer Anti-TNF-alpha therapies: the next generation Nat. Rev. Drug Discovery 2 2003 736 746
32. W.M. Pardridge, Y.S. Kang, J. Yang, and J.L. Buciak Enhanced cellular uptake and in vivo biodistribution of a monoclonal antibody following cationization J. Pharm. Sci. 84 1995 943 948
33. W.S. Putnam, S. Prabhu, Y. Zheng, M. Subramanyam, and Y.M. Wang Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies Trends Biotechnol. 28 2010 509 516
34. M. Raghavan, V.R. Bonagura, S.L. Morrison, and P.J. Bjorkman Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants Biochemistry 34 1995 14649 14657
35. J.R. Rojas, R.P. Taylor, M.R. Cunningham, T.J. Rutkoski, J. Vennarini, H. Jang, M.A. Graham, K. Geboes, S.D. Rousselle, and C.L. Wagner Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys J. Pharmacol. Exp. Ther. 313 2005 578 585 (Pubitemid 40604157)
36. D.C. Roopenian, and S. Akilesh FcRn: the neonatal Fc receptor comes of age Nat. Rev. Immunol. 7 2007 715 725 (Pubitemid 47327396)
37. C. Shen, G.V. Assche, S. Colpaert, P. Maerten, K. Geboes, P. Rutgeerts, and J.L. Ceuppens Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept Aliment. Pharmacol. Ther. 21 2005 251 258 (Pubitemid 40278362)
38. T. Suzuki, A. Ishii-Watabe, M. Tada, T. Kobayashi, T. Kanayasu-Toyoda, T. Kawanishi, and T. Yamaguchi Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR J. Immunol. 184 2010 1968 1976
39. P.C. Taylor, and M. Feldmann Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis Nat. Rev. Rheumatol. 5 2009 578 582
40. M. Tyagi, M. Rusnati, M. Presta, and M. Giacca Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans J. Biol. Chem. 276 2001 3254 3261
41. T. Yeung, G.E. Gilbert, J. Shi, J. Silvius, A. Kapus, and S. Grinstein Membrane phosphatidylserine regulates surface charge and protein localization Science 319 2008 210 213
42. Y.A. Yeung, M.K. Leabman, J.S. Marvin, J. Qiu, C.W. Adams, S. Lien, M.A. Starovasnik, and H.B. Lowman Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates J. Immunol. 182 2009 7663 7671
43. Y.A. Yeung, X. Wu, A.E. Reyes 2nd, J.M. Vernes, S. Lien, J. Lowe, M. Maia, W.F. Forrest, Y.G. Meng, L.A. Damico, N. Ferrara, and H.B. Lowman A therapeutic anti-VEGF antibody with increased potency independent of pharmacokinetic half-life Cancer Res. 70 2010 3269 3277